Rolfs A et al. |
Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients. |
2013 |
PLoS ONE |
pmid:24278166
|
Cabrera-Salazar MA et al. |
Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease. |
2012 |
PLoS ONE |
pmid:22912851
|
Sun Y et al. |
Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease. |
2012 |
J. Biol. Chem. |
pmid:22167193
|
Zhang CK et al. |
Genome-wide association study of N370S homozygous Gaucher disease reveals the candidacy of CLN8 gene as a genetic modifier contributing to extreme phenotypic variation. |
2012 |
Am. J. Hematol. |
pmid:22388998
|
Li YT et al. |
Selective extraction and effective separation of galactosylsphingosine (psychosine) and glucosylsphingosine from other glycosphingolipids in pathological tissue samples. |
2011 |
Neurochem. Res. |
pmid:21136152
|
Xu YH et al. |
Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. |
2011 |
Mol. Genet. Metab. |
pmid:21257328
|
Dekker N et al. |
Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. |
2011 |
Blood |
pmid:21868580
|
Auray-Blais C et al. |
How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? |
2010 |
Clin. Chim. Acta |
pmid:20716442
|
Sun Y et al. |
Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. |
2010 |
Hum. Mol. Genet. |
pmid:20047948
|
Imokawa G |
A possible mechanism underlying the ceramide deficiency in atopic dermatitis: expression of a deacylase enzyme that cleaves the N-acyl linkage of sphingomyelin and glucosylceramide. |
2009 |
J. Dermatol. Sci. |
pmid:19443184
|
Mogi C et al. |
Sphingosylphosphorylcholine antagonizes proton-sensing ovarian cancer G-protein-coupled receptor 1 (OGR1)-mediated inositol phosphate production and cAMP accumulation. |
2005 |
J. Pharmacol. Sci. |
pmid:16210776
|
Deguchi H et al. |
Sphingolipids as bioactive regulators of thrombin generation. |
2004 |
J. Biol. Chem. |
pmid:14722105
|
Okamoto R et al. |
Sphingosylphosphorylcholine is upregulated in the stratum corneum of patients with atopic dermatitis. |
2003 |
J. Lipid Res. |
pmid:12518027
|
Lloyd-Evans E et al. |
Lyso-glycosphingolipids mobilize calcium from brain microsomes via multiple mechanisms. |
2003 |
Biochem. J. |
pmid:12917012
|
Tayebi N et al. |
Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? |
2003 |
Mol. Genet. Metab. |
pmid:12809640
|
Ishibashi M et al. |
Abnormal expression of the novel epidermal enzyme, glucosylceramide deacylase, and the accumulation of its enzymatic reaction product, glucosylsphingosine, in the skin of patients with atopic dermatitis. |
2003 |
Lab. Invest. |
pmid:12649340
|
Park JK et al. |
Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup. |
2003 |
Pediatr. Res. |
pmid:12595585
|
Bodennec J et al. |
Simultaneous quantification of lyso-neutral glycosphingolipids and neutral glycosphingolipids by N-acetylation with [3H]acetic anhydride. |
2003 |
J. Lipid Res. |
pmid:12730305
|
Schueler UH et al. |
Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3. |
2003 |
Neurobiol. Dis. |
pmid:14678774
|
Lloyd-Evans E et al. |
Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms. |
2003 |
J. Biol. Chem. |
pmid:12709427
|